Key facts
- Xihua Scientific’s last known valuation is $613.8M (Mar 2023).
- It has raised $199.5M; the latest was PE Growth/Expansion in Feb 2026.
- Notable investors include HSG (Hong Kong), Legend Capital, Highlight Capital, SJ Jiacheng Investment Management, China Merchants Capital — 26 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for Xihua Scientific
- ·The full record, as it builds
Funding rounds
No funding rounds for Xihua Scientific are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xihua Scientific
Provider of clinical research services created to offer global pharmaceutical companies with high-quality, high-efficiency full-process and integrated services from self-produced drug development to marketing approval. The company provides clinical trial design, laboratory analysis and statistical analysis for pharmaceutical developers, enabling clients to more efficiently bring their new medicine to market.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2015
- Employees
- 657
- Website
- xihuasci.com/
- Ownership
- Privately Held (backing)
Xihua Scientific doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xihua Scientific shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xihua Scientific in its N-PORT filings yet. We sweep new filings monthly.